Advanced

Allergic contact dermatitis caused by isobornyl acrylate in OmniPod, an innovative tubeless insulin pump

Raison-Peyron, Nadia; Mowitz, Martin LU ; Bonardel, Nathalie; Aerts, Olivier and Bruze, Magnus LU (2018) In Contact Dermatitis 79(2). p.76-80
Abstract

Background: The frequency of allergic contact dermatitis caused by (meth)acrylates is increasing worldwide, and isobornyl acrylate (IBOA) has been identified as a culprit sensitizer in FreeStyle Libre, a medical device used by diabetic patients. Objectives: To report on 4 patients sensitized to IBOA contained in OmniPod, a new, tubeless insulin pump, and to describe the clinical and chemical analytical work-up. Method: Four patients with eczematous skin eruptions after using OmniPod, including 2 with previous adverse skin reactions to FreeStyle Libre, were patch tested with a baseline series and additional (meth)acrylates, including IBOA in several concentrations and/or vehicles. Gas chromatography-mass spectrometry (GC-MS) was used to... (More)

Background: The frequency of allergic contact dermatitis caused by (meth)acrylates is increasing worldwide, and isobornyl acrylate (IBOA) has been identified as a culprit sensitizer in FreeStyle Libre, a medical device used by diabetic patients. Objectives: To report on 4 patients sensitized to IBOA contained in OmniPod, a new, tubeless insulin pump, and to describe the clinical and chemical analytical work-up. Method: Four patients with eczematous skin eruptions after using OmniPod, including 2 with previous adverse skin reactions to FreeStyle Libre, were patch tested with a baseline series and additional (meth)acrylates, including IBOA in several concentrations and/or vehicles. Gas chromatography-mass spectrometry (GC-MS) was used to identify the presence of IBOA in OmniPod. Results: All patients were shown to be sensitized to IBOA. GC-MS identified IBOA in OmniPod, with the highest concentrations being found in the unit itself and not in the adhesive patch. Conclusions: The OmniPod tubeless insulin pump is another source of IBOA, and its use may lead to primary sensitization to this acrylate, or may provoke elicitation of allergic contact dermatitis in previously sensitized patients. Our cases highlight the need to obtain satisfactory cooperation from pharmaceutical companies involved in the manufacture of these widely used medical devices.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adhesive, Allergic contact dermatitis, CAS no. 5888-33-5, Case report, Diabetes mellitus, Gas chromatography-mass spectrometry, Insulin pump, Isobornyl acrylate, Medical device, OmniPod
in
Contact Dermatitis
volume
79
issue
2
pages
76 - 80
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • scopus:85045220070
ISSN
0105-1873
DOI
10.1111/cod.12995
language
English
LU publication?
yes
id
5c93f829-3aca-4d80-8cdd-6d926070749d
date added to LUP
2018-04-23 10:59:47
date last changed
2019-01-14 17:04:44
@article{5c93f829-3aca-4d80-8cdd-6d926070749d,
  abstract     = {<p>Background: The frequency of allergic contact dermatitis caused by (meth)acrylates is increasing worldwide, and isobornyl acrylate (IBOA) has been identified as a culprit sensitizer in FreeStyle Libre, a medical device used by diabetic patients. Objectives: To report on 4 patients sensitized to IBOA contained in OmniPod, a new, tubeless insulin pump, and to describe the clinical and chemical analytical work-up. Method: Four patients with eczematous skin eruptions after using OmniPod, including 2 with previous adverse skin reactions to FreeStyle Libre, were patch tested with a baseline series and additional (meth)acrylates, including IBOA in several concentrations and/or vehicles. Gas chromatography-mass spectrometry (GC-MS) was used to identify the presence of IBOA in OmniPod. Results: All patients were shown to be sensitized to IBOA. GC-MS identified IBOA in OmniPod, with the highest concentrations being found in the unit itself and not in the adhesive patch. Conclusions: The OmniPod tubeless insulin pump is another source of IBOA, and its use may lead to primary sensitization to this acrylate, or may provoke elicitation of allergic contact dermatitis in previously sensitized patients. Our cases highlight the need to obtain satisfactory cooperation from pharmaceutical companies involved in the manufacture of these widely used medical devices.</p>},
  author       = {Raison-Peyron, Nadia and Mowitz, Martin and Bonardel, Nathalie and Aerts, Olivier and Bruze, Magnus},
  issn         = {0105-1873},
  keyword      = {Adhesive,Allergic contact dermatitis,CAS no. 5888-33-5,Case report,Diabetes mellitus,Gas chromatography-mass spectrometry,Insulin pump,Isobornyl acrylate,Medical device,OmniPod},
  language     = {eng},
  month        = {04},
  number       = {2},
  pages        = {76--80},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {Contact Dermatitis},
  title        = {Allergic contact dermatitis caused by isobornyl acrylate in OmniPod, an innovative tubeless insulin pump},
  url          = {http://dx.doi.org/10.1111/cod.12995},
  volume       = {79},
  year         = {2018},
}